Fusion Pharmaceuticals Inc.

Fusion Pharmaceuticals Inc. (FUSN) priced its initial public offering on Jun 26, 2020 at $17.00 per share, above its $14.00–$16.00 range, raising $212.5M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $708.3M. Morgan Stanley was lead-left underwriter, joined by Jefferies, TD Cowen and Wedbush. Goodwin Procter and Osler advised the company and Latham & Watkins and Torys advised the underwriters.

Fusion Pharmaceuticals Inc. is a clinical-stage oncology company developing radiopharmaceuticals as precision medicines. Its Targeted Alpha Therapies platform and Fast-Clear linker technology connect alpha particle emitting isotopes to antibodies and other molecules to deliver radiation to tumors; its lead candidate is FPI-1434.

Status

IPO

Ticker

FUSN

Exchange

Nasdaq Global Select

Priced

Jun 26, 2020

IPO price

$17.00

Price range

$14.00–$16.00

Raised

$212.5M

Market cap at IPO price

$708.3M

First filed

Jun 5, 2020

Underwriters

Morgan Stanley, Jefferies, TD Cowen and Wedbush

Company counsel

Goodwin Procter and Osler

Underwriters' counsel

Latham & Watkins and Torys

Sector

Biotech & pharma

Country / state

Ontario, Canada

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.